Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Peking University Third Hospital | OTHER |
| Chinese PLA General Hospital | OTHER |
| Peking University International Hospital | OTHER |
Not provided
Not provided
Not provided
Not provided
This research study will evaluate how near-infrared fluorescence (NIRF) imaging with low-dose second window indocyanine green (ICG) can assist in the radical resection and pathologic diagnosis of malignant soft tissue sarcoma, such as dermatofibrosarcoma protuberans (DFSP) and skin squamous cell carcinoma (sSCC) during surgery.
To improve the accuracy of radical resection by reducing the risk of missed diagnosis of positive margin, this study will explore clinical application of near-infrared fluorescence imaging with modified low-dose SWIG technique in guiding radical resection of malignant soft tissue tumor. The investigators conduct a multi-center, multi-subgroup, prospective randomized controlled trial. The participants will be first stratified according to histological type involving dermatofibrosarcoma protuberans (DFSP) and skin squamous cell carcinoma (sSCC). The patients with DFSP or sSCC will be then randomly assigned to three groups. Patients in the control group will not receive ICG administration. The ICG was injected intravenously 24 hours before surgery, at a dose of 0.25 mg/kg in the first experimental group and 25 mg/patient in the second experimental group, respectively. The patients in the control groups will undergo traditional assessment of surgical margins.The patients in the experimental groups, on the other hand, will be scheduled to intraoperative near-infrared fluorescence imaging to scan gross tumor, tumor bed and cross-sectional specimen. The 2-year local recurrence rate will be regarded as primary outcome. The number of positive margins will be compared among groups. The investigators will also calculate the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) with 95% confidence intervals based on fluorescent signal of tumor bed in the experimental groups.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patients with DFSP in the first experimental group | Experimental | The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group. |
|
| Patients with DFSP in the second experimental group | Experimental | The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group. |
|
| Patients with DFSP in the control group | No Intervention | ||
| Patients with sSCC in the first experimental group | Experimental | The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group. |
|
| Patients with sSCC in the second experimental group | Experimental | The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group. |
|
| Patients with sSCC in the control group |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| ICG administration | Drug | The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group. |
|
| Measure | Description | Time Frame |
|---|---|---|
| 2-year local recurrence rate | up to 24 months |
| Measure | Description | Time Frame |
|---|---|---|
| number of positive margins | through study completion, an average of 2 years | |
| sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) | through study completion, an average of 2 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Dr. Han | Contact | +86-15001222456 | hanyudi_301@foxmail.com |
Not provided
Not provided
Not provided
| Label | URL |
|---|---|
| Related Info | View source |
Not provided
The IPD will include patient characteristics, tumor location, tumor size and histological type and grade. The number of positive margins will be recorded. The sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) will also be calculated. The adverse effects between first and second experimental groups will be compared. The 2-year local recurrence rate will be viewed as primary outcome.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ICG administration | Drug | The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group. |
|
| ICG administration | Drug | The ICG was injected intravenously 24 hours before surgery at a dose of 0.25 mg/kg in the first experimental group |
|
| ICG administration | Drug | The ICG was injected intravenously 24 hours before surgery at a dose of 25 mg/patient in the second experimental group. |
|
| Adverse effects | through study completion, an average of 2 years |
| ID | Term |
|---|---|
| D018223 | Dermatofibrosarcoma |
| ID | Term |
|---|---|
| D005354 | Fibrosarcoma |
| D018218 | Neoplasms, Fibrous Tissue |
| D009372 | Neoplasms, Connective Tissue |
| D018204 | Neoplasms, Connective and Soft Tissue |
| D009370 | Neoplasms by Histologic Type |
| D009369 | Neoplasms |
| D012509 | Sarcoma |
Not provided
Not provided